Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2025 08:05 ET | Source: Prime Medicine, Inc.

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
November 25, 2025 08:00 ET | Source: Prime Medicine, Inc.

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
November 11, 2025 08:00 ET | Source: Prime Medicine, Inc.

Prime Medicine to Present at Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
November 07, 2025 10:21 ET | Source: Prime Medicine, Inc.

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647 as...
November 07, 2025 07:00 ET | Source: Prime Medicine, Inc.

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647 as...
November 03, 2025 08:01 ET | Source: Prime Medicine, Inc.

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
October 30, 2025 16:01 ET | Source: Prime Medicine, Inc.

Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
October 07, 2025 08:00 ET | Source: Prime Medicine, Inc.

Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
August 26, 2025 08:00 ET | Source: Prime Medicine, Inc.

Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
August 07, 2025 08:00 ET | Source: Prime Medicine, Inc.

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory...